Executive Overview
Seasonal influenza remains one of public health’s most persistent adversaries, driving 3 to 5 million cases of severe illness and up to 650,000 deaths worldwide each year. Beyond its annual burden, the virus carries the persistent threat of global disruption, having fueled historic pandemics such as the catastrophic 1918 Spanish Flu. For decades, virologists have understood the broad strokes of how the virus operates: once it breaches a host cell, it releases viral RNA that commandeers cellular machinery, converting the host into a dedicated factory for producing new viral particles.
However, precisely how this microscopic hijacking unfolds at a molecular level inside living, intact cells has remained stubbornly opaque. Traditional biochemical techniques have long forced scientists to lyse—or break apart—cells to study protein interactions, a process that frequently distorts cellular reality, prompts artifactual protein contacts, and destroys weak or transient molecular handshakes.
In a landmark study published in Nature Microbiology, an interdisciplinary team of researchers at EMBL Hamburg and the Leibniz Research Institute for Molecular Pharmacology (FMP) in Berlin has shattered these methodological limitations. By developing an innovative, customized workflow that merges advanced cross-linking mass spectrometry (XL-MS) with a modified version of the Nobel Prize-winning protein structure prediction tool, AlphaFold, the researchers have generated an unusually detailed, high-resolution structural map of how influenza A reshapes human cells.
This breakthrough not only captures direct virus-human protein interactions in their native cellular context for the first time, but it also uncovers two distinct strategies the virus employs to dominate its host: engineering the proper folding of its surface proteins while systematically dissolving vital nuclear defense structures known as paraspeckles. By providing an unprecedented view of the infection interface, this research lays a foundational roadmap for the future design of highly targeted antiviral therapeutics and next-generation vaccines.
Detailed Chronology
The Mechanics of Infection and the Traditional Blind Spot
To understand the significance of the recent breakthroughs at EMBL Hamburg and FMP, one must first examine the life cycle of the influenza A virus. Upon entering a human cell, the virus sheds its outer envelope and releases its viral RNA into the cytoplasm or nucleus. This RNA package carries precise instructions for synthesizing a specialized cadre of viral proteins. Once manufactured, these proteins disperse throughout the host architecture, systematically disrupting normal cellular functions and re-routing metabolic and structural systems to assemble progeny virions.
For years, mapping this takeover meant relying on traditional biochemical assays. Scientists would infect cell cultures, lyse the cells to harvest their contents, and use affinity purification or immunoprecipitation to isolate interacting proteins. While these methods yielded vast lists of potential protein-protein interactions, they suffered from a fatal flaw: destruction of the cellular environment.
When a cell is broken apart, its internal compartments—which normally segregate distinct biochemical processes—rupture. Proteins that never encounter one another in a living cell suddenly collide in a test tube, generating false positives. Conversely, weak, transient, or location-specific interactions vital to an active infection dissolve and vanish. Consequently, researchers were left with incomplete, error-prone catalogs of viral-host interfaces, unable to determine which molecular connections were authentic drivers of disease.
The Breakthrough: In-Cell Cross-Linking Mass Spectrometry
Recognizing the desperate need for in-cell structural data, the EMBL Hamburg team connected with Boris Bogdanow and Fan Liu at FMP Berlin. Bogdanow and Liu had been engineering a specialized variant of cross-linking mass spectrometry (XL-MS) designed explicitly for virus-infected, intact cells.
XL-MS involves introducing chemical cross-linkers—molecular "staples"—into living, infected cells. These cross-linkers covalently bind adjacent amino acid residues on proteins that are physically touching or in extremely close proximity. Once the interactions are "frozen" in place, the cells can be safely lysed, and the cross-linked peptides are isolated and analyzed using advanced mass spectrometry.
This specialized adaptation allowed the team to capture interactions that occur only briefly or within tightly restricted microenvironments of an infected cell. It provided the structural precision necessary to model how interacting viral and human proteins fit together geometrically, bridging the gap between raw biochemical detection and structural biology.
Integrating Experimental Data with AlphaFold
Acquiring massive datasets of cross-linked peptides is only half the battle; interpreting their spatial arrangement within complex macromolecular assemblies is notoriously difficult. To solve this puzzle, the researchers turned to artificial intelligence, utilizing a modified version of AlphaFold, the groundbreaking protein structure prediction algorithm developed by Google DeepMind.
Standard computational modeling of virus-host complexes often produces unreliable predictions because the structural biology of viral proteins interacting with human cellular machinery is exceptionally diverse and poorly conserved. However, by feeding their experimental XL-MS data directly into the AlphaFold pipeline, the researchers bypassed these predictive hurdles.
The cross-linking data served as a physical spatial constraint, telling the computational model precisely which regions of the viral and host proteins were neighbors inside the living cell. This hybrid experimental-computational strategy yielded high-confidence structural models of protein complexes that were previously thought to be impervious to accurate prediction.
Supporting Context & Metrics
The Global Toll of Influenza
- Annual Burden: Seasonal influenza is responsible for 3 to 5 million cases of severe illness globally every year.
- Mortality: The virus claims between 290,000 and 650,000 lives annually due to respiratory and secondary complications.
- Pandemic Potential: Influenza A is uniquely infamous for its historical disruptive capacity, having caused multiple global pandemics, most notably the 1918 Spanish Flu, which infected an estimated one-third of the global population and resulted in tens of millions of deaths.
Institutional Collaboration and Technological Infrastructure
The success of this comprehensive mapping initiative depended on a sophisticated, multi-institutional technological pipeline:
- Cross-Linking Mass Spectrometry (XL-MS): Conducted at Charité – Universitätsmedizin Berlin and the Leibniz Research Institute for Molecular Pharmacology (FMP).
- Glycoproteomics Analysis: Performed at the EMBL Proteomics Core Facility.
- Computational Modeling: Executed on the high-performance EMBL Compute Cluster using customized AlphaFold architectures.
- Microscopy and Imaging: Carried out at the Advanced Light and Fluorescence Microscopy (ALFM) Facility at the Centre for Structural Systems Biology (CSSB) in Hamburg.
Two Defining Hijacking Strategies
The published findings in Nature Microbiology illuminated two primary mechanisms by which influenza A asserts dominance over human cells:
- Hemagglutinin Maturation and Folding: The researchers tracked hemagglutinin, the primary surface glycoprotein the virus uses to bind and penetrate host cells. As this protein transits the cell’s internal transport and processing network—the endoplasmic reticulum and Golgi apparatus—it requires precise folding and chemical modification. The mapping data revealed that specific human host proteins, some previously harboring poorly understood biological functions, are co-opted to act as chaperones, ensuring the correct structural maturation of hemagglutinin during infection.
- Dissolution of Nuclear Paraspeckles: In a surprising twist, the team discovered that influenza A infection causes the systematic dissolution of paraspeckles—small, droplet-like ribonucleoprotein bodies located within the cell nucleus. When these structures break apart, they release sequestered RNA-binding proteins, which the virus repurposes to facilitate its own replication while simultaneously dismantling the cell’s antiviral gene regulation and stress response machinery.
Official Statements
The implications of this research extend far beyond academic virology, offering a new paradigm for how host-pathogen interactions are investigated. Principal investigators and lead authors emphasized the transformative nature of the methodology:
"Our work provides a new way to study flu-host interactions in their native context and with structural insight. The current results are a snapshot of a moment during infection, and it opens the door to studying flu-host interactions across the entire infection cycle."
— Jan Kosinski, Group Leader at EMBL Hamburg and Centre for Structural Systems Biology (CSSB)
Addressing the methodological breakthrough achieved through cross-linking mass spectrometry, Boris Bogdanow noted the direct translational benefits for drug discovery:
"XL-MS allows us to capture protein-protein interactions directly in infected intact cells, while also providing structural information about how these interactions are happening. This gives us insight into the interface between the virus and the human cell and may, through structural modeling, help identify actionable targets for future pharmaceutical interventions."
— Boris Bogdanow, Junior Research Group Leader at the Institute of Virology, Charité – Universitätsmedizin Berlin
Highlighting the unexpected discovery regarding nuclear architecture, Iuliia Kotova pointed to the consistency of the viral manipulation across diverse biological models:
"What surprised us most was the paraspeckles. Watching these tiny organelles in the nucleus dissolve, consistently across every cell line and every flu strain we tested, told us this isn’t a side effect of infection — it might be a strategy."
— Iuliia Kotova, former predoctoral fellow at the Kosinski Group at EMBL Hamburg, currently at ETH Zurich, and first author of the study
Future Outlook
By successfully bridging in-cell structural biology, mass spectrometry, and artificial intelligence, the collaborative team at EMBL Hamburg, FMP, and Charité has established a powerful new blueprint for virological research. While this initial study utilized a laboratory-adapted strain of influenza A, the methodological framework is inherently modular and adaptable.
The researchers are already setting their sights on expanding the workflow across the entirety of the viral infection cycle to capture chronological shifts in protein-protein interfaces. More importantly, they aim to pivot the technology toward high-consequence pathogens with severe pandemic potential, such as avian influenza strains (e.g., H5N1).
Uncovering the precise interaction networks that allow these lethal strains to cross species barriers and multiply efficiently in human cells could unveil universal vulnerabilities. Ultimately, by pinpointing exact structural interfaces where the virus depends on human machinery, this research paves the way for the development of broad-spectrum antiviral therapeutics capable of outsmarting mutating respiratory pathogens before the next global health crisis strikes.